Larvol Delta - aTyr-Pharma-Announces-Phase-2-Study-of-Efzotimod-in-Patients-with-Systemic-SclerosisAssociated-Interstitial-Lung-Disease-SScILD-Following-FDA-Clearance-of-IND-Application

Stalaris (efzofitimod) - aTyr Pharma, Kyorin

https://www.globenewswire.com/news-release/2023/03/01/2618148/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-Efzofitimod-in-Patients-with-Systemic-Sclerosis-Associated-Interstitial-Lung-Disease-SSc-ILD-Following-FDA-Clearance-of-IND-Application.html

Mar 1, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next